Aditxt (ADTX) Stock Surges 49% on Clinical Trial Proposal
Aditxt (ADTX) stock is soaring after a major update on a clinical trial for early ovarian cancer detection, driving heavy ...
- Latest
- Trending
Aditxt (ADTX) stock is soaring after a major update on a clinical trial for early ovarian cancer detection, driving heavy ...
Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.
AbCellera Biologics Inc. progresses with their TCE platform and strategic partnerships, aiming for CTA submissions in Q2 2025.
"Blockchain tech in healthcare set to soar, driven by data security needs, with market growth expected to hit $9706.49M by ...
Formation Bio secures $372M Series D led by Sanofi to enhance AI-driven drug development, focusing on workflow automation and AI ...
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Bharat Biotech admits patent oversight on Covaxin, pledges to include ICMR scientists in new filings to uphold transparency and legal ...
America's crackdown on Chinese biotech could lead to drug shortages and higher costs, impacting patients without delivering promised security benefits.
Robert Azelby sells $20,215 in ADC Therapeutics shares for tax reasons; holds 53,005 shares. Investors eye insider actions for future ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.